Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SLP 
Simulations Plus Inc (SLP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SLP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25.33
1 Year Target Price $25.33
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.7% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 285.80M USD | Price to earnings Ratio - | 1Y Target Price 25.33 |
Price to earnings Ratio - | 1Y Target Price 25.33 | ||
Volume (30-day avg) 6 | Beta 0.76 | 52 Weeks Range 12.39 - 37.72 | Updated Date 08/15/2025 |
52 Weeks Range 12.39 - 37.72 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -78.62% | Operating Margin (TTM) 18.15% |
Management Effectiveness
Return on Assets (TTM) 2.74% | Return on Equity (TTM) -41.49% |
Valuation
Trailing PE - | Forward PE 52.91 | Enterprise Value 258073962 | Price to Sales(TTM) 3.56 |
Enterprise Value 258073962 | Price to Sales(TTM) 3.56 | ||
Enterprise Value to Revenue 3.21 | Enterprise Value to EBITDA 18.78 | Shares Outstanding 20127100 | Shares Floating 16624792 |
Shares Outstanding 20127100 | Shares Floating 16624792 | ||
Percent Insiders 17.38 | Percent Institutions 82.2 |
Upturn AI SWOT
Simulations Plus Inc
Company Overview
History and Background
Simulations Plus, Inc. was founded in 1996. It focuses on developing and marketing simulation and modeling software, and consulting services supporting drug development, chemical safety assessment, and regulatory submissions.
Core Business Areas
- Software: Develops and sells simulation software for pharmaceutical, biotechnology, and chemical industries.
- Consulting: Offers consulting services utilizing its software to assist clients in drug development and regulatory submissions.
Leadership and Structure
The company is led by its CEO. The structure involves various departments including software development, sales & marketing, consulting, and finance.
Top Products and Market Share
Key Offerings
- GastroPlus: A physiologically-based pharmacokinetic (PBPK) modeling platform used to predict drug absorption, distribution, metabolism, and excretion (ADME) in humans and animals. Market share is substantial in PBPK modeling, revenue not publicly specified. Competitors include Certara's Simcyp and Open Systems Pharmacology's PK-Sim.
- ADMET Predictor: Software that predicts ADMET properties of chemical compounds, used for drug discovery. Market share is significant in ADMET prediction; revenue data is not publicly specified. Competitors include Schru00f6dinger's ADMET tools and Lhasa Limited.
- DILIsym: Predicts Drug Induced Liver Injury. Competitors include Instem's CyNEXUS and Physiomics.
Market Dynamics
Industry Overview
The industry involves simulation and modeling software and consulting services for pharmaceutical and chemical industries. Key drivers are regulatory requirements for drug development, increasing R&D costs, and the need for efficient drug discovery and development.
Positioning
Simulations Plus is positioned as a leading provider of PBPK modeling and ADMET prediction software and services, with a focus on accuracy and innovation.
Total Addressable Market (TAM)
The global pharmaceutical simulation software market is projected to reach billions of dollars. Simulations Plus is positioned to capture a significant portion of this market by offering comprehensive simulation capabilities.
Upturn SWOT Analysis
Strengths
- Strong expertise in PBPK modeling and ADMET prediction
- Established customer base
- High-quality software products
- Consulting expertise
Weaknesses
- Relatively small size compared to larger competitors
- Dependence on pharmaceutical and chemical industries
- Limited brand awareness outside core markets
Opportunities
- Expanding into new applications of simulation and modeling
- Acquiring complementary technologies
- Increasing sales to emerging markets
- Partnerships with other software companies
Threats
- Competition from larger companies
- Technological obsolescence
- Changes in regulatory requirements
- Economic downturns impacting pharmaceutical R&D spending
Competitors and Market Share
Key Competitors
- CTRA
- TMO
- INCY
Competitive Landscape
Simulations Plus benefits from its specialized expertise. Larger competitors have broader product offerings. The competitive landscape is driven by technological innovation and customer service.
Major Acquisitions
Cognigen Corporation
- Year: 2015
- Acquisition Price (USD millions): 37
- Strategic Rationale: Expanded consulting services and PBPK modeling capabilities.
Growth Trajectory and Initiatives
Historical Growth: Simulations Plus has demonstrated consistent revenue and profit growth over the past years.
Future Projections: Analysts expect continued growth in revenue and EPS, driven by increasing demand for simulation and modeling software in drug development.
Recent Initiatives: Simulations Plus has undertaken strategic initiatives to expand its product offerings and customer base.
Summary
Simulations Plus is a strong company with a focus on simulation and modeling software for the pharmaceutical industry. Its specialized expertise and established customer base are working well. The company should continue to watch out for competition from larger players and maintain its technological advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Financial Reports
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Simulations Plus Inc
Exchange NASDAQ | Headquaters Research Triangle Park, NC, United States | ||
IPO Launch date 1997-06-18 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 243 | Website https://www.simulations-plus.com |
Full time employees 243 | Website https://www.simulations-plus.com | ||
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.